secwatch.observer — SEC 8-K summary
======================================

Issuer:     RELMADA THERAPEUTICS, INC. (RLMD)
CIK:        0001553643
Form:       8-K
Filed at:   2024-05-30T23:59:59+00:00
Accession:  0001213900-24-047968
Event type: other_material
Sentiment:  negative
Materiality: 0.15
Item codes: 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Relmada shareholders reject equity plan increase and say-on-pay at annual meeting
--------------------------------------------------------------------------------

- Director John Glasspool received 7.7M for and 9.98M withheld; Paul Kelly had 11.8M for, 5.88M withheld.
- Ratification of Marcum LLP as auditor approved: 19.98M for, 1.97M against.
- Proposal to increase 2021 Equity Plan by 4.5M shares failed: 4.26M for, 13.41M against.
- Advisory vote on executive compensation did not pass: 7.53M for, 10.12M against.
- 72.9% of outstanding shares (21.99M of 30.17M) were present at the meeting.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1553643/000121390024047968/0001213900-24-047968-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1553643/000121390024047968/ea0207126-8k_relmada.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-047968

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer